From: Integrated cervical cancer screening in Mayuge District Uganda (ASPIRE Mayuge): a pragmatic sequential cluster randomized trial protocol
CIN2+
CIN3
Sensitivity
90.8%(84.7–95.0%)
92.3%(84.8–96.9%)
Specificity
42.6%(38.5–46.9%)
40.0%(36.1–44.0%)